Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4436 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

SuperGen shares retreat on cancer drug withdrawal

Orathecin (rubitecan) capsules is SuperGen’s investigational drug for the treatment of pancreatic cancer patients who have failed at least one prior chemotherapy regimen. SuperGen’s decision to withdraw the

Neuro3d completes $42.9 million funding

The new funds will be used to continue the clinical development of Neuro3d’s broad pipeline of innovative drug candidates targeting psychiatric disorders such as schizophrenia, depression and anxiety,

Pfizer nerve drug may see setbacks

Lyrica (pregabalin capsules) have received FDA approval for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved

Biovail begins legal action over antidepressant generics

The formulation for Wellbutrin XL (bupropion hydrochloride extended-release tablets) was developed by Biovail, which licensed the product’s worldwide (excluding Canada) sales and distribution rights to GlaxoSmithKline in October

BMS and Somerset pen antidepressant deal

Under the terms of the agreement, Bristol-Myers Squibb will receive exclusive distribution rights to commercialize Emsam (selegiline transdermal system), if approved, in the US and Canada, with an